These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28416449)

  • 1. Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.
    Mastellos DC; Reis ES; Ricklin D; Smith RJ; Lambris JD
    Trends Immunol; 2017 Jun; 38(6):383-394. PubMed ID: 28416449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
    Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ
    Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement inhibition in C3 glomerulopathy.
    Nester CM; Smith RJ
    Semin Immunol; 2016 Jun; 28(3):241-9. PubMed ID: 27402056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.
    Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD
    Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.
    Mastellos DC; Ricklin D; Hajishengallis E; Hajishengallis G; Lambris JD
    Mol Oral Microbiol; 2016 Feb; 31(1):3-17. PubMed ID: 26332138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M; Emma F
    Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.
    Chauvet S; Roumenina LT; Aucouturier P; Marinozzi MC; Dragon-Durey MA; Karras A; Delmas Y; Le Quintrec M; Guerrot D; Jourde-Chiche N; Ribes D; Ronco P; Bridoux F; Fremeaux-Bacchi V
    Front Immunol; 2018; 9():2260. PubMed ID: 30333829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic control of complement activation at the level of the central component C3.
    Ricklin D; Lambris JD
    Immunobiology; 2016 Jun; 221(6):740-6. PubMed ID: 26101137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
    Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD
    Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases.
    Meuleman MS; Grunenwald A; Chauvet S
    Semin Immunol; 2022 Mar; 60():101634. PubMed ID: 35817659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 glomerulopathy and current dilemmas.
    Ito N; Ohashi R; Nagata M
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 dependent, C5 independent immune complex glomerulopathy in the mouse.
    Sawtell NM; Hartman AL; Weiss MA; Pesce AJ; Michael JG
    Lab Invest; 1988 Mar; 58(3):287-93. PubMed ID: 2964544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [C3 glomerulopathy].
    Chauvet S; Servais A; Frémeaux-Bacchi V
    Nephrol Ther; 2014 Apr; 10(2):78-85. PubMed ID: 24508002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for C3 glomerulopathy.
    Nester CM; Smith RJ
    Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):231-7. PubMed ID: 23318699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
    Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
    Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complement system regulation and C3 glomerulopathy].
    Xiao HJ; He RJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):323-6. PubMed ID: 23591359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Challenges and Promise of Complement Therapeutics for Ocular Diseases.
    Park DH; Connor KM; Lambris JD
    Front Immunol; 2019; 10():1007. PubMed ID: 31156618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.
    Ruseva MM; Peng T; Lasaro MA; Bouchard K; Liu-Chen S; Sun F; Yu ZX; Marozsan A; Wang Y; Pickering MC
    J Am Soc Nephrol; 2016 Feb; 27(2):405-16. PubMed ID: 26047789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.